Abstract: An apparatus and method for generating a controlled, predictable, reproducible and variable-size distribution of particulate matter (PM), particle number (PN) and/or facsimile/simulation, derived from vaporizing and condensing a specialized liquid, utilizing a vapor delivery device; a filter capability so as to remove a significant amount of ambient PM/PN as a secondary calibration process for the identification of fine and ultra-fine particles (e.g., 0.3 micrometers and smaller) as well as a computer-controlled ability to perform a pre-determined series of calibration routines, housed in a container.

Abstract: An apparatus and method for generating a controlled, predictable, reproducible and variable-size distribution of particulate matter (PM), particle number (PN) and/or facsimile/simulation, derived from vaporizing and condensing a specialized liquid, utilizing a vapor delivery device; a filter capability so as to remove a significant amount of ambient PM/PN as a secondary calibration process for the identification of fine and ultra-fine particles (e.g., 0.3 micrometers and smaller) as well as a computer-controlled ability to perform a pre-determined series of calibration routines, housed in a container.

Abstract: An apparatus and method for generating a controlled, predictable, reproducible and variable-size distribution of particulate matter (PM), particle number (PN) and/or facsimile/simulation, derived from vaporizing and condensing a specialized liquid, utilizing a vapor delivery device; a filter capability so as to remove a significant amount of ambient PM/PN as a secondary calibration process for the identification of fine and ultra-fine particles (e.g., 0.3 micrometers and smaller) as well as a computer-controlled ability to perform a pre-determined series of calibration routines, housed in a container.

Abstract: An apparatus and method for generating a controlled, predictable, reproducible and variable-size distribution of particulate matter (PM), particle number (PN) and/or facsimile/simulation, derived from vaporizing and condensing a specialized liquid, utilizing a vapor delivery device; a filter capability so as to remove a significant amount of ambient PM/PN as a secondary calibration process for the identification of fine and ultra-fine particles (e.g., 0.3 micrometers and smaller) as well as a computer-controlled ability to perform a pre-determined series of calibration routines, housed in a container.

Abstract: An apparatus and method for generating a controlled, predictable, reproducible and variable-size distribution of particulate matter (PM), particle number (PN) and/or facsimile/simulation, derived from vaporizing and condensing a specialized liquid, utilizing a vapor delivery device; a filter capability so as to remove a significant amount of ambient PM/PN as a secondary calibration process for the identification of fine and ultra-fine particles (e.g., 0.3 micrometers and smaller) as well as a computer-controlled ability to perform a pre-determined series of calibration routines, housed in a container.

Abstract: An apparatus and method for generating a controlled, predictable, reproducible and variable-size distribution of particulate matter (PM), particle number (PN) and/or facsimile/simulation, derived from vaporizing and condensing a specialized liquid, utilizing a vapor delivery device; a filter capability so as to remove a significant amount of ambient PM/PN as a secondary calibration process for the identification of fine and ultra-fine particles (e.g., 0.3 micrometers and smaller) as well as a computer-controlled ability to perform a pre-determined series of calibration routines, housed in a container.

Abstract: The present invention relates to an improved transdermal hydroalcoholic testosterone gel formulation that provides, among other things, a desirable pharmacokinetic hormone profile, and methods of use.

Abstract: The present invention relates to an improved transdermal hydroalcoholic testosterone gel formulation that provides, among other things, a desirable pharmacokinetic hormone profile, and methods of use.

Abstract: The present invention relates to an improved transdermal hydroalcoholic testosterone gel formulation that provides, among other things, a desirable pharmacokinetic hormone profile, and methods of use.

Abstract: The present invention relates to an improved transdermal hydroalcoholic testosterone gel formulation that provides, among other things, a desirable pharmacokinetic hormone profile, and methods of use.

Abstract: A system for tracking compliance to risk management policies for a given enterprise that provides risk status feedback on hierarchical managerial levels. The system notifies users of potential problems with non-compliance of enterprise policies set on a high level of enterprise management, and prompts the users to take steps to achieve compliance. The enterprise policies are designed to protect the enterprise from various forms of risk associated with enterprise activities. Accordingly, minimizing risk across enterprise operations, subdivisions, projects and applications produces an overall benefit of reduced liability or exposure to liability for the entire enterprise. A compliance status is provided by business groups at all levels of the enterprise, and consolidated for each management level to which the risk status is promoted.

Abstract: In various embodiments, the present invention provides pharmaceutical compositions comprising delta-9-THC and to methods of administering such compositions to a patient in need of delta-9-THC therapy.

Abstract: An intranasal drug product is provided including an antipsychotic drug, such as haloperidol, in sprayable solution in an intranasal metered dose sprayer. Also provided is a method of administering an antipsychotic drug, such as haloperidol, to a patient, including the step of delivering an effective amount of the antipsychotic drug to a patient intranasally using an intranasal metered dose sprayer. A method of treating a psychotic episode also is provided, the method including the step of delivering an antipsychotic drug, such as haloperidol, intranasally in an amount effective to control the psychotic episode.

Abstract: A system for tracking compliance with policies related to management of risk for a given enterprise provides risk status feedback on a number of managerial levels. The system notifies users of potential problems with non-compliance of enterprise policies set on a high level of enterprise management, and prompts the users to take steps to achieve compliance. The enterprise policies are designed to protect the enterprise from various forms of risk associated with enterprise activities. Accordingly, minimizing risk across enterprise operations, subdivisions, projects and applications produces an overall benefit of reduced liability or exposure to liability for the entire enterprise. A compliance status is provided by business groups at all levels of the enterprise, and consolidated for each management level to which the risk status is promoted.